Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price RuleGlobeNewsWire · Sep 29, 2026
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapyGlobeNewsWire · Aug 24, 2026
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common StockGlobeNewsWire · Aug 18, 2026
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price RequirementGlobeNewsWire · Aug 13, 2026Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.